Clinical Significance of Human Cytochrome P450 1A2 Ontogeny and Its Gene Polymorphism
GAO Xiang-bo1,2, JIANG Zhou-hong1, WANG Yu-mei1, YU Lu-shan2, NI Shao-qing1*
1. Children��s Hospital, Zhejiang University School of Medicine, Hangzhou 310052, China; 2. College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
Abstract��The change of human cytochrome P450 1A2 ontogeny and the effect of its gene polymorphism on clinical medication were reviewed. The relevant literatures from various databases were searched, collected, analyzed and summarized. CYP1A2 is one of the major subfamilies in human liver enzyme. It is involved in metabolism of about 8%-10% of drugs in clinic, which has important pharmacological and toxicological implications.The expression and activity of CYP1A2 enzymes were different during development, which had a significant effect on clinical medication in human. Studies can see clearance rates and elimination half-lives differences by using caffeine as a probe substrate.Gene polymorphisms cause activity differences of CYP1A2. Gene polymorphisms of CYP1A2*1C and CYP1A2*1F, have been extensively studied show significant effects on clinical medication in adults.There are very few studies on medication between CYP1A2 gene polymorphism and enzyme activity in premature infants, infants and children. The effect of CYP1A2 enzyme activity is unknown between gene polymorphism and ontogeny interaction during human development.It is very necessary to further study the ontogeny changes of CYP1A2 and its gene polymorphism on drug metabolism for improving the safety and efficacy medication in children.
HINES R N, MCCARVER D G. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther, 2002, 300(2):355-360.
[2]
JOHANSSON I, INGELMAN-SUNDBERG M. Genetic polymorphism and toxicology--with emphasis on cytochrome p450. Toxicol Sci, 2011, 120(1):1-13.
[3]
WANG B, ZHOU S F. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem, 2009, 16(31):4066-4218.
[4]
KLEIN K, WINTER S, TURPEINEN M, et al. Pathway-targeted pharmacogenomics of CYP1A2 in human liver. Front Pharmacol, 2010, 1:129.
[5]
CAZENEUVE C, PONS G, REY E, et al. Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults. Br J Clin Pharmacol, 1994, 37(5):405-412.
[6]
SCHMIDT R J, ROMITTI P A, BURNS T L, et al. Caffeine, selected metabolic gene variants, and risk for neural tube defects. Birth Defects Res A Clin Mol Teratol, 2010, 88(7):560-569.
[7]
DE KESEL P M, LAMBERT W E, STOVE C P. CYP1A2 phenotyping in dried blood spots and microvolumes of whole blood and plasma. Bioanalysis, 2014, 6(22):3011-3024.
[8]
JORDAN N Y, MIMPEN J Y, VAN DEN BOGAARD W J M, et al. Analysis of caffeine and paraxanthine in human saliva with ultra-high-performance liquid chromatography for CYP1A2 phenotyping. J Chromator B, 2015, 995-996: 70-73.
[9]
PERERA V, GROSS A S, XU H, et al. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. J Pharm Pharmacol, 2011, 63(9):1161-1168.
[10]
HAKOOZ N M. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities. Curr Drug Metab, 2009, 10(4):329-338.
[11]
CHEN Y, OUYANG D S, TAN Z R, et al. Determination of caffeine and five metabolites simultaneously by HPLC and application on evaluating the activity of CYP1A2, CYP2A6, NAT2 and XO in Chinese healthy volunteers . Chin J Clin Pharmacol Ther (�й��ٴ�ҩ��ѧ������ѧ), 2007, 12(10):1175-1176.
[12]
OSHIKOYA K A, SAMMONS H, SMITH K, et al. Lack of a significant change in caffeine metabolism in underweight children as determined by the caffeine breath test. Arch Dis Child, 2015,100(7):689-693.
[13]
ZHENG T H, LIU W, LI S P, et al. Effect of five kinds of CYP450 enzymes in different acute liver injury rat models. Chin Pharm J(�й�ҩѧ��־), 2017, 52(12):1023-1028.
[14]
TANG J, WANG Z T. Determination of CYP1A2 and CYP2D1 activities in rat liver microsomes and kinetic studies using ultra performance liquid chromatography tandem mass spectrometry . Chin Pharm J(�й�ҩѧ��־), 2015, 50(12):1043-1047.
[15]
YUAN R, MADANI S, WEI X X, et al. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos, 2002, 30(12):1311-1319.
[16]
SONNIER M, CRESTEIL T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem, 1998, 251(3):893-898.
[17]
SONG G, SUN X, HINES R N, et al. Determination of human hepatic CYP2C8 and CYP1A2 age-dependent expression to support human health risk assessment for early ages. Drug Metab Dispos, 2017, 45(5):468-475.
[18]
TATEISHI T, NAKURA H, ASOH M, et al. A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci, 1997, 61(26):2567-2574.
[19]
TATEISHI T, ASOH M, YAMAGUCHI A, et al. Developmental changes in urinary elimination of theophylline and its metabolites in pediatric patients. Pediatr Res, 1999, 45(1):66-70.
[20]
LAMBERT G H, SCHOELLER D A, KOTAKE A N, et al. The effect of age, gender, and sexual maturation on the caffeine breath test. Dev Pharmacol Ther, 1986, 9(6):375-388.
[21]
AKINYINKA O O, SOWUNMI A, HONEYWELL R, et al. The pharmacokinetics of caffeine in nigerian children suffering from malaria and kwashiorkor. Eur J Clin Pharmacol, 2000, 56(2):153-158.
[22]
LEE T C, CHARLES B, STEER P, et al. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clin Pharmacol Ther, 1997, 61(6):628-640.
[23]
CHARLES B G, TOWNSEND S R, STEER P A, et al. Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. Ther Drug Monit, 2008, 30(6):709-716.
[24]
LEE H S, KHOO Y M, CHIRINO-BARCELO Y, et al. Caffeine in apnoeic Asian neonates: a sparse data analysis. Br J Clin Pharmacol, 2002, 54(1):31-37.
[25]
THOMSON A H, KERR S, WRIGHT S. Population pharmacokinetics of caffeine in neonates and young infants. Ther Drug Monit, 1996, 18(3):245-253.
[26]
WU M Z. Population pharmacokinetic study of caffeine in the prevention and treatment of premature infant. Guangzhou: Guangzhou Medical University, 2017.
[27]
ARANDA J V, COLLINGE J M, ZINMAN R, et al. Maturation of caffeine elimination in infancy. Arch Dis Child, 1979, 54(12):946-949.
[28]
PONS G, CARRIER O, RICHARD M O, et al. Developmental changes of caffeine elimination in infancy. Dev Pharmacol Ther, 1988, 11(5):258-264.
[29]
WHITE J R, PADOWSKI J M, ZHONG Y, et al. Pharmacokinetic analysis and comparison of caffeine administered rapidly or slowly in coffee chilled or hot versus chilled energy drink in healthy young adults. Clin Toxicol, 2016, 54(4):308-312.
[30]
BJORKMAN S.Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol, 2005, 59(6):691-704.
[31]
JOHNSON T N, ROSTAMI-HODJEGAN A, TUCKER G T. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet, 2006, 45(9):931-956.
[32]
EDGINTON A N, SCHMITT W, VOITH B, et al. A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet,2006, 45(7):683-704.
[33]
SALEM F, JOHNSON T N, ABDULJALIL K, et al. A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. Clin Pharmacokinet, 2014, 53(7):625-636.
[34]
LU J M, ZHU L, LI J, et al. Pharmacokinetics of caffeine citrate and the progress of its application in the treatment for apnea of prematurity . Chin Pharm J(�й�ҩѧ��־), 2017,52(21):1884-1888.
[35]
XIN Q, LIANG G W, LIU M, et al. Establishment of detection method for CYP1A2*1F and its effect on agomelatine pharmacokinetics. Pharm Biotechnol(ҩ�����＼��), 2014,21(6):506-510.
[36]
YUAN H W, ZHAO X F, TANG L, et al. Associationstudy of cytochrome P450 1A2 mRNA expression with serumconcentration and efficacy ofclozapine. J Psychiatry(����ҽѧ��־), 2011,24(1):11-14.
[37]
AKLILLU E, CARRILLO J A, MAKONNEN E, et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression:characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol, 2003, 64(3):659-669.
[38]
WOODING S P, WATKINS W S, BAMSHAD M J, et al. DNA sequence variation in a 3.7-kb noncoding sequence 5�� of the CYP1A2 gene: implications for human population history and natural selection. Amj Hum Genet, 2002, 71(3):528-542.
[39]
THORN C F, AKLILLU E, KLEIN T E, et al. Pharm GKB summary: very important pharmacogene information for CYP1A2. Pharmacogenet Genomics, 2012, 22(1):73-77.
[40]
SOHN J A, KIM H S, OH J, et al. Prediction of serum theophylline concentrations and cytochrome P450 1A2 activity by analyzing urinary metabolites in preterm infants. Br J Clin Pharmacol, 2017, 83(6):1279-1286.
[41]
KIM S E, KIM B H, LEE S, et al. Population pharmacokinetics of theophylline in premature Korean infants. Ther Drug Monit, 2013, 35(3):338-344.
[42]
AL-AHMAD M M, AMIR N, DHANASEKARAN S, et al. Genetic polymorphisms of cytochrome P450-1A2 (CYP1A2) among Emiratis. PLoS One, 2017, 12(9):e0183424.
[43]
LI Z, LI A Y. Cytochrome oxidase CYP1A2*C gene polymorphism influencing anesthesia effect of ropivacaine hydrochlorid . China Med Engineer(�й�ҽѧ����), 2017,25(5):10-14.
[44]
WANG L, HU Z, DENG X, et al. Association between common CYP1A2 polymorphisms and theophylline metabolism in non-smoking healthy volunteers. Basic Clin Pharmacol, 2013, 112(4):257-263.
[45]
XIONG S J, LI L L. The effect of CYP1A2 gene polymorphism on the metabolism of theophylline. Exp Ther Med, 2018,15(1):109-114.
[46]
YIM E Y, KANG H R, JUNG J W, et al. CYP1A2 polymorphism and theophylline clearance in Korean non-smoking asthmatics. Asia Pac Allergy, 2013, 3(4):231-240.
[47]
SACHSE C, BROCKMOLLER J, BAUER S, et al. Functional significance of a C>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol, 1999, 47(4):445-449.
[48]
KOONRUNGSESOMBOON N, KHATSRI R, WONGCHOMPOO P, et al. The impact of genetic polymorphismson CYP1A2 activity in humans: a systematic review and Meta-analysis. Pharmacogenomics J, 2018, 18(6):760-768.
[49]
SHAO F. Study on the effect of CYP1A2 gene polymorphism on the pharmacokinetics of agomelatine. Hefei:Anhui University of Chinese Medicine,2016.
[50]
LAIKA B, LEUCHT S, HERES S, et al. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J, 2009, 10(1):20-29.
[51]
CZERWENSKY F, LEUCHT S, STEIMER W.CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations. Ther Drug Monit, 2015, 37(2):152-160.
[52]
NA TAKUATHUNG M, HANPRASERTPONG N, TEEKACHUNHATEAN S, et al. Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and Meta-analysis. Acta Psychiat Scand, 2019, 139(1):15-25.
[53]
DJORDJEVIC N, MILOVANOVIC D D, RADOVANOVIC M, et al. CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy. Eur J Clin Pharmacol, 2016, 72(4):439-445.
[54]
BOHANEC G P, ROZMAN B, TOMI M, et al. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol, 2008, 64(9):871-876.
[55]
HOPKINS A M, WIESE M D, PROUDMAN S M, et al. Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. Br J Clin Pharmacol, 2016, 81(1):113-123.
[56]
IVANOVA S A, TOSHCHAKOVA V A, FILIPENKO M L, et al. Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility. World J Biol Psychiatry, 2015, 16(3):200-205.
[57]
BACKMAN J T, KARJALAINEN M J, NEUVONEN M, et al. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol, 2006, 62(3):345-357.
[58]
LI Y, LIU L, WANG X, et al. In vivo assessment of the effect of CYP1A2 inhibition and induction on pomalidomide pharmacokinetics in healthy subjects. J Clin Pharmacol, 2018, 58(10):1295-1304.
[59]
YEH R F, GAVER V E, PATTERSON K B, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr, 2006, 42(1):52-60.
[60]
JACOBS B S, COLBERS A P, VELTHOVEN-GRAAFLAND K, et al. Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers. Int J Antimicrob Agents, 2014, 44(2):173-177.
[61]
NI S Q, WANG J, ZHAO Z Y,et al. Changeof cytochrome P450 3A inthe processof development and its clinical significance . Chin Pharm J(�й�ҩѧ��־), 2009, 44(5):321-323.
[62]
FDA. Table of pharmacogenomicbiomarkers in drug labeling with labeling text. 2018-06.https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm.
2019, Vol. 54 
